Back to sessions
Sep 30
Education

EDU 41 - Riding the Waves of New Small Cell Lung Cancer Therapeutics

Room 155/157
12:45pm - 02:00pm PT
Lung Cancer/Thoracic Malignancies

MODERATOR(S)

Percy Lee, MD, FASTRO - City of Hope National Medical Center

session DESCRIPTION

This session will discuss current evidence for radiotherapy in the management of SCLC. New phase III data combining radiation and immunotherapy (Adriatic, LU-005) will be presented, with particular attention on the importance of timing of immunotherapy relative to chemoradiation. Nuances in the timing of radiation, commonly delivered dose fractionations, and new data on the relative benefits of dose escalation, whether with once a day or twice a day treatment will be discussed. The relative merits and risks of consolidative thoracic radiation and stereotactic radiotherapy in extensive stage SCLC will be explored. Novel systemic options with T-cell engagers, antibody drug conjugates (ADCs) will be discussed in the context of extensive stage SCLC in the context of future combinations with consolidative radiation therapy. Finally, case-based scenarios highlighting pertinent clinical pearls of the above scenarios will be presented, with discussion among all speakers.

learning objectives

  1. Evaluate the evidence for optimal dose fractionations, timing of radiotherapy and immunotherapy for limited stage SCLC.
  2. Identify and discuss the controversies on the use of thoracic radiotherapy in extensive stage SCLC.
  3. Review emerging systemic options such as T-cell engagers, antibody drug conjugates (ADCs) for extensive stage SCLC.

Credits

AMA PRA Category 1 Credits: 1.25
CAMPEP Credits: 1.25
MDCB Credits: 1.25
EVALUATION

Presentations